Lung Function and Inflammatory Responses in Healthy Young Adults Exposed to 0.06 ppm Ozone for 6.6 Hours

Chong S Kim¹, Neil E Alexis², Ana G Rappold¹, Howard Kehrl¹, Milan J Hazucha², John C Lay², Mike T Schmitt¹, Martin Case¹, Robert B Devlin¹, David B Peden², and David Diaz-Sanchez¹

¹USEPA National Health and Environmental Effects Research Laboratory, RTP, NC and ²Center for Environmental Medicine, Asthma and Lung Biology, University of North Carolina, Chapel Hill, NC.

¹Address Correspondence: Chong S. Kim, Ph.D., Environmental Public Health Division (MD-58B), National Health and Environmental Effects Research Laboratory, US Environmental Protection Agency, Research Triangle Park, NC 27711; Telephone: 919-966-5049; Fax: 919-966-6367; E-mail: kim.chong@epa.gov.

Funding: USEPA, CR83346301 USEPA cooperative agreement, NIH RC1ES018417, NIH R01ES012706

Running head: Effects of ozone at 0.06 ppm concentration

Descriptor number: 6.16

At a Glance Commentary
Scientific knowledge on the subject:
Inhalation of ozone causes decrements in lung function and an increase in airway inflammation at concentrations near the current Ambient Ozone Standard. It is not known what the effects are at concentrations lower than this.

What this study adds to the field:
This study reports for the first time that acute exposure to ozone for 6.6 hours at a level of 0.06 ppm (a level below the current Ambient Ozone Standard) causes significant effects on pulmonary function and airway inflammation in healthy young adults.
Abstract

Rationale: Exposure to ozone causes a decrease in spirometric lung function and an increase in airway inflammation in healthy young adults at concentrations as low as 0.08 ppm close to the National Ambient Air Quality Standard for ground level ozone.

Objectives: To test whether airway effects occur below the current ozone standard and if they are more pronounced in potentially susceptible individuals, such as those deficient in the antioxidant gene glutathione S-transferase M1. Methods: Pulmonary function and subjective symptoms were measured in 59 healthy young adults (19-35 years) immediately before and after exposure to 0.0 (clean air, CA) and 0.06 ppm ozone for 6.6 hours in a chamber while undergoing intermittent moderate exercise. The polymorphonuclear neutrophil (PMN) influx was measured in 24 subjects 16-18 hour post-exposure. Measurements and Main Results: Subjects experienced a significantly greater (p=0.008) change in FEV\textsubscript{1} (±standard error) immediately following exposure to 0.06ppm ozone compared to CA (-1.76±0.50% vs. -0.002±0.46%). The decrement in FVC was also greater (p=0.02) after ozone vs. CA (-2.32±0.41% vs. -1.13±0.34%). Similarly, changes in %PMN were greater after ozone (54.0±4.6%) than CA (38.3±3.7%) exposure (p<0.001). Symptom scores were not different between ozone vs. CA. There were no significant differences in changes in FEV\textsubscript{1}, FVC and %PMN between subjects with GSTM1-positive and GSTM1-null genotypes. Conclusions: Exposure of healthy young adults to 0.06 ppm ozone for 6.6 hours causes a significant decrement of FEV\textsubscript{1} and increase in neutrophilic inflammation in the airways. GSTM1 genotype alone appears to have no significant role in modifying the effects.

Number of words: 250

Key words: pulmonary function, airway inflammation, polymorphism, ozone exposure, exercise
Introduction

Ozone is a major component of photochemical smog. Controlled human exposure studies have been critical in demonstrating that it can cause decrements in lung function (1-7) and lung inflammation (8-11). While the majority of these studies involved exposures to relatively high (0.1 – 0.4 ppm) concentrations for short periods of time (typically 2 hours), prolonged exposure studies at lower levels were largely responsible for the EPA lowering the National Ambient Air Quality Standard for ground level ozone in 2008. Several studies have now confirmed the initial observation of Horstman et al (4) that exposure of healthy young adults to 0.08 ppm ozone for 6.6 hrs while undergoing intermittent moderate exercise will result in a significant (5-8 %) drop in forced expired volume at 1 s (FEV$_1$) (5,6). Similarly, studies using this exposure regime demonstrated that 0.08 ppm ozone can initiate inflammatory responses in the lungs of healthy young adults (9), characterized by increases in polymorphonuclear neutrophils (PMN) in bronchoalveolar lavage fluid collected 24 hours postexposure. Recently, we have confirmed and extended these findings in 15 healthy young adults by showing a significant increase in sputum neutrophilic inflammation 18 hours post-exposure to 0.08 ppm ozone (12).

Recent community-based air pollution studies using emergency department records have reported associations for increased risk of pediatric asthma at very low ozone concentrations (13). This has led some to question whether adverse responses could occur in healthy adults at concentrations below the current standard. However, only two controlled human exposures have investigated this and none to our knowledge have addressed inflammatory effects. Adams reported that healthy young adults exposed to multiple ozone concentrations experienced a significant decrease in lung function at 0.08 ppm but not at 0.06 ppm or 0.04 ppm (7). However,
a secondary analysis by others of the same data concluded that 0.06 ppm may have induced a change in FEV\textsubscript{1} (14). In 2009, Schelegle et al (15) reported that healthy young volunteers exposed to step-wise ozone concentrations experienced a significant decrement of FEV\textsubscript{1} at concentrations as low as 0.07 ppm but not at 0.06 ppm.

Large heterogeneity in responses to ozone between individuals has been reported (16, 17). Ozone exerts oxidant stress and results in airway inflammation and therefore genes which modulate inflammation and antioxidant defense mechanisms have been proposed as potential effect modifiers. In particular, glutathione S-transferase (GST) M1 has attracted attention as it is present in the airways, and gene deletions (GSTM1-null genotype) can be present in up to 50\% of the population, resulting in complete absence of the enzyme. This polymorphism has been associated with reduced lung function (18, 19), and numerous epidemiology and controlled exposure studies have suggested that it may confer susceptibility to increased airway inflammation to ozone as well as other oxidant air pollutants (20, 21).

More than 100 million people in the U.S now live in the counties that do not meet the current ozone standard and public health consequences are enormous. In the present study, we performed a randomized controlled human exposure crossover study and investigated specifically if exposure of healthy young adults to 0.06 ppm ozone for 6.6 hrs with exercise would cause measurable airway effects assessed by pulmonary function (chosen a priori to be FEV\textsubscript{1} and FVC) and inflammatory markers (sputum PMN). We also examined if responses were more pronounced in individuals with the GSTM1-null genotype. Some of the preliminary results of these studies have been previously reported in the form of abstracts (22).
Methods

Subjects

Fifty-nine healthy young adult subjects aged 19 - 35 years, with no history of smoking in the past 2 years completed the study. All subjects underwent a screening procedure that included a complete medical history and physical examination and a pregnancy test for females. Exclusion criteria included respiratory illness or symptoms within 4 weeks or a positive pregnancy test. All subjects were genotyped for GSTM1. The study protocol was approved by the Institutional Review Board at the University of North Carolina Medical School in Chapel Hill and the EPA and informed consent was obtained from all subjects prior to their participation in the study. Subject characteristics and baseline lung function test values are shown in Table 1.

Study design

The study design was similar to those used in previous studies (4, 7) to facilitate comparison. Each subject was exposed to 0.00 ppm (clean air, CA) and 0.06 ppm ozone for 6.6 hours with moderate exercise in a stainless steel chamber (4 x 6 x 3.2m). Exposures were randomized, double-blinded and separated by at least 1 week. Minute ventilation ($V_E$) was measured hourly and exercise levels adjusted to $V_E = 20 \text{ L/min/m}^2 \text{BSA}$ to ensure that subjects breathed consistently throughout exposure. Spirometric lung function and symptom scores were assessed immediately before and after the 6.6 hour exposure period. Sputum was collected the next morning approximately 16-18 hours post exposure. Exposures were conducted only during the cool weather season in Chapel Hill (November – March) to minimize exposure to elevated ambient ozone.
Study protocol

*Training Day*

On a training day, all subjects were trained for lung function measurements. Settings for the treadmill and bicycle ergometer required to produce a desired value of minute ventilation was determined for each subject.

*Exposure day*

On the day of each exposure, subjects were assessed for vital signs, completed a symptom questionnaire and performed pre-exposure lung function spirometry and body plethysmography maneuvers. They then entered the chamber set for the appropriate condition (CA or 0.06 ppm ozone), and began exercising for a 50-min period at 20 liters/min/m² body surface area in $V_E$ followed by a 10 min rest period. The exercise session was repeated six times alternating between the treadmill and bicycle with $V_E$ maintained within ±2 L/min of the subject’s target value. Subjects were also given 35-min to eat lunch. Thus, they remained in the chamber for a total of 6.6 hours during which ventilatory parameters (minute ventilation, tidal volume, breathing frequency) were measured and electrocardiac signals, heart rate and blood oxygen saturation monitored continuously to ensure subject safety. Subjects were exposed in pairs (of the same sex). At the end of exposure, spirometric and plethysmographic lung function measurements were performed and a symptom questionnaire was obtained.

*Follow up day*

On the next morning, subjects returned to the laboratory and sputum samples were collected.
**Measurements**

Spirometry was performed on a 10.2-liter dry seal digital spirometer interfaced to a computer (SensorMedics Model 1022, Palm Springs, CA). At least three sets of qualified data were obtained and the largest value selected for FEV$\textsubscript{1}$ and FVC as per ATS guidelines (23). Pulmonary function on all subjects was measured using one dedicated spirometer and by one certified pulmonary function technician to minimize variability. Specific airway resistance ($\text{sR}_{aw}$) was assessed by body plethysmography (SensorMedics Model V6200) and the average of two highest values out of 3-5 measurements obtained. Measurements were performed before and immediately after exposure for use in endpoint analysis. Additional spirometry measurements were performed in the chamber during 10 min rest periods primarily for monitoring subject safety and were not necessarily performed by the same technician.

Symptoms were assessed before and after 6.6 hour exposure. The subjects were asked to rate the severity of cough, pain on deep inspiration (PDI), shortness of breath (SOB) and throat irritation on a five-point scale ranging from 0 (none) to 4 (most severe). Subjects recorded the severity score directly on the computerized questionnaire. Total symptom severity was obtained by adding scores of all four symptoms.

GSTM1 genotypes were determined using real-time polymerase chain reaction as previously described by Gilliland *et al* (24) from DNA isolated from white blood cells using the QIAamp DNA Mini Kit (Qiagen Inc., Valencia, CA).
Sputum collection and analysis

Sputum samples were obtained and processed by the method described by Alexis et al (25). Briefly, subjects underwent sputum induction with hypertonic saline. Acquired samples were subjected to plug selection and subsequent treatment with dithiothreitol. Cell viability and total cell counts were evaluated and differential cell counts examined (Hema-Stain3, Fisher Scientific). Acquired sputum samples considered acceptable for processing had a minimum of 75 mg of selected plug material, cell viability >50% and squamous epithelial cells <40%. All sample processing and slide preparations were performed on the same day of collection.

Ozone generation and monitoring

Ozone was generated by a silent electric discharge method (Model 502, Meckenheim, Bonn, Germany) and introduced into the chamber that was maintained at 22 ± 1.0°C and 40 ± 5% relative humidity. The concentration of ozone was continuously monitored using UV photometric analyzers (TECO Model 49, Thermo Scientific, MA) that were periodically calibrated for ±5% accuracy by NIST traceable ozone calibrator (TECO Model 49PS).

Data and Statistical analyses

The lung function endpoints were expressed as percent changes from the pre-exposure (or baseline) values for each subject. Neutrophil content in the sputum samples was expressed as percent of total cell count (%PMN) and the measurements following each exposure were compared. Linear mixed effects models with a subject specific random intercept was used to test changes in response endpoints between clean air and ozone exposures at the group level in order to account for subject level variability and repeated measures. The effect of GSTM1 and separately gender, was examined using a two factor mixed effects model with repeated measures
on a single factor, exposure and subject level random effects. We report the magnitude and direction of the expected change along with its associated 95% equal two tail confidence intervals. R statistical software (Version 2.10.1) was used for the analyses. Alpha of 0.05 was used to determine statistical significance.

Results

Exercise and minute ventilation

Means of six hourly measurements of $V_E$, tidal volume, breathing frequency and heart rate during 6.6 hour exposure to CA and ozone are summarized in Table 2. Overall, there was no difference in both ventilation parameters and heart rates between CA and 0.06 ppm ozone exposure.

Exposure to 0.06 ppm Ozone Causes Decrements in Lung Function

The primary hypothesis tested in this study was that exposure to 0.06 ppm ozone would decrease FEV$_1$ and FVC after 6.6 hours. The results are summarized in Table 3. Exposure to ozone resulted in a 1.76±0.50% (mean ±SEM) decrease in FEV$_1$ compared to virtually no change (0.002±0.46%) after exposure to clean air (Figure 1A). Thus, relative to clean air, exposure to 0.06 ppm ozone for 6.6 hours resulted in a 1.75±0.64% decrement in FEV$_1$ ($p=0.008$). These decrements did not appear to be driven by a small subset of subjects (Figure 1B). Of the 59 individuals studied, only three subjects showed >10% drop after ozone exposure. Similarly, FVC decreased by 2.32±0.41% after ozone exposure vs. 1.13±0.34% after clean air (Figure 1C). Ozone exposure thus caused a relative decrement of 1.19±0.51% ($p=0.02$). Again, individual response to ozone exposure was mostly within ±5% change as shown in Figure 1D. Changes in other lung function parameters (FEF$_{25-75}$%, FEF$_{max}$ and sR$_{aw}$) were not significant.
A second aim of the study was to determine the role of GSTM1 in determining responses to ozone. While both genotypes had decrements in FEV₁ following ozone exposure relative to air, changes were only statistically significant for GSTM1-positive subjects (Figure 2A). However, the difference in FEV₁ response between GSTM1-null and –positive subjects was not statistically significant (p=0.72). Similarly, females had a significant decrement in CA-adjusted FEV₁ (2.02±0.88%, p=0.02), while males did not (1.44±0.95%, p=0.14), but the difference between genders was not significant (p=0.66). No difference between GSTM1-null vs. -positive and males vs. females were seen for FVC (Figure 2B).

**Exposure to 0.06 ppm Ozone Causes Pulmonary Inflammation**

This study is the first to examine ozone concentrations below the current standard to cause pulmonary inflammation. The results are summarized in Table 4. Graphic illustration in Figure 3A shows that ozone exposure alters the airway milieu as evidenced by increases in %PMN in induced sputum samples. Following air exposure, %PMN averaged 38.3±3.7%. In contrast, ozone-exposed samples average 54.0±4.6%. Thus, relative to clean air, ozone exposure resulted in a 15.7±3.1% increase in %PMN for the whole group (p<0.002). Of the 24 subjects studied, all but five subjects showed an ozone-induced increase in %PMNs and 10 showed ≥20% increase (Figure 3B).

Figure 4 shows a significant increase in ozone-induced %PMN for both GSTM1-null (20.0%; 95% CI 11.0-29.0; p=0.001) and GSTM1-positive subjects (11.3%; 95% CI 2.3-20.3; p=0.02). Those carrying the null allele had a stronger response (p=0.001) than those carrying the positive
allele (p=0.02); however, the estimate of the modifying effect of GSTM1 did not reach significance (p=0.17; also see Table 4). Both males (24.2%; 95% CI 15.8-32.6; p=0.001) and females (8.5%; 95% CI 0.79-16.20; p=0.03) had statistically significant increases in ozone-induced %PMNs. The modifying effect of gender was significant (p=0.009). The changes in %PMN were not accompanied by changes in total cell numbers for the whole group or any subgroup following ozone vs. air. Total cell counts in sputum samples were 5.05(±0.82) x 10^6 after CA and 6.93(±1.52) x 10^6 after ozone (p=NS vs. CA) for the whole group.

**Symptom Questionnaire**

Of fifty-six subjects who had no symptoms at baseline, twenty subjects reported symptoms after either CA or 0.06 ppm ozone exposure. The most commonly reported symptom was throat irritation followed by shortness of breath, pain on deep inspiration and cough. The mean (±SEM) total symptom score (TSS) was 0.43±0.11 for CA and 0.41±0.11 for ozone (P=NS vs. CA). For genotype subgroups, TSS was 0.40±0.16 for CA and 0.47±0.17 for ozone in *GSTM1-positive* subjects and 0.46±0.16 for CA and 0.35±0.13 for ozone in *GSTM1-null* subjects (P=NS vs. CA for both group). The score and nature of the symptoms were similar between CA and ozone exposures.

**Discussion**

In 2008 the U.S. EPA revised National Ambient Air Quality Standard for ground level ozone down to 0.075 ppm (3-year average of the fourth highest daily maximum 8-hour average) (26). This was based primarily on controlled human chamber studies of FEV\textsubscript{1} changes post-exposure after 6.6 hours. Inflammation of the airway, as well as toxicology and epidemiology studies was
used as supportive evidence. In this study, we demonstrate, using the same exposure approach, decrements in FEV\textsubscript{1} and FVC at a concentration (0.06ppm) below the current standard. Furthermore, we demonstrate increased neutrophil airways inflammation at this low ozone concentration.

To date, two previous studies have investigated lung function at 0.06ppm ozone using a 6.6 hour protocol; neither found statistically significant effects (7, 15) even though their observed effect size was greater than in our study. For example, they reported clean air-adjusted FEV\textsubscript{1} after 0.06 ppm ozone decrements of 3.52% and 2.86%, while we observed a smaller drop of 1.75%, yet our results were highly statistically significance (p=0.008). Similarly, our reported change in FVC of 1.18% was statistically significant (p=0.02), although in the range of the 3.16% and 0.45% reported previously (7, 15). The key difference between the previous and the current study is that while theirs were designed to compare multiple concentrations at multiple time points, ours was specifically designed to limit the need for multiple comparisons.

In order to accomplish this we employed several strategies to increase the statistical power and to minimize experimental variability. Firstly, our analysis was focused on only one ozone concentration and a comparison to clean air. Secondly, we enrolled nearly twice as many subjects (N=59) as previous studies, as the study was powered to examine the differences between two GSTM1 polymorphisms. Thirdly, our analysis was determined a priori to focus only on changes observed immediately post-exposure for lung function. Similarly, analysis of airway inflammation was limited to %PMN 16-18hr after exposure. Fourthly, we used only one dedicated pulmonary technician and spirometer for primary lung function measurements. Lastly,
our studies were performed exclusively in the winter season during which ambient ozone level was lower than 0.06 ppm (see Figure E1 in the online data supplement) and thus, potential influence of prior exposure to ambient ozone was minimized.

Our results may have significant public health implications. Although most subjects (>60%) showed a <10% decrease in lung function after 0.06 ppm ozone, 3 of 59 subjects in the present and 2 of 30 subjects in the Adams’ study (7) showed a lung function decrement >10%. This suggests that 0.06 ppm ozone will cause lung function decrements in the majority of young individuals with some 6% (e.g. 5 of 89 subjects) of them having a greater response. In addition, this is the first study to examine and observe airway inflammatory effects for ozone at concentration levels below 0.08 ppm. Chronic airway inflammation may cause airway damage and thereby bronchoconstriction and bronchial hyperresponsiveness. An increase in neutrophilic inflammation has been shown to be strongly associated with exacerbation of airway disease in asthmatics. Thus, ozone is uniquely associated with worsening of asthma and increased hospitalization in asthmatic children (13). Although the current study is limited to healthy subjects, the health consequences may be more severe in individuals with preexisting diseases particularly in asthma.

Effects of gender on response to ozone exposure have been reported variably. Some studies found a greater response in FEV\textsubscript{1} in female than in male subjects whereas others found a comparable response between them, mostly after a short-term exposure to high concentration ozone (27, 28). For a prolonged exposure to low concentration ozone, most studies report combined results of both males and females with no specific analysis for gender effects (6, 7,
The studies, however, appear to have assumed or found no gender effects in pulmonary function response. In our study, FEV$_1$ and FVC decrement was not significant in males but was significant in females; however, we found no significant difference between males and females. In contrast, %PMN was increased significantly in both genders with males showing a greater response than females (p=0.009). Thus, it appears that ozone sensitivity may differ between genders depending on end points.

A two factor mixed effects model with repeated measures was used to test if there was a difference in FEV$_1$ responses between GSTM1-positive and GSTM1-null subjects. We did not find such an association in both FEV$_1$ and FVC. This was consistent with earlier studies (20, 29) that have shown no independent role of GSTM1-null genotype on lung function decrement. The role of GSTM1-null, however, may become evident when it presents with other genotypes (NQO1 and GSTP1) (19, 29). With regard to airway neutrophilia, although the difference was not significant, GSTM1-null subjects appeared to have a greater neutrophilic inflammatory response than GSTM1-positive subjects. A sample size estimate, however, revealed that the non-significant increase would likely become significant with a larger cohort of approximately 47 subjects, which would be consistent with our earlier report on response of GSTM1-null genotype to 0.4 ppm ozone (20). This seemingly contradicting trend vs. lung function response may be due to differences in the putative modes of action of ozone. While changes in lung function are thought to occur via activation of a subset of airway C-fibers (30), inflammation is thought to originate from activation of Nf-kB induced by reactive oxygen species generation (31). Thus, corticosteroids can blunt ozone-induced neutrophilia but not lung function responses (32). GSTM1 is thought to act by reducing oxidative stress including detoxification of byproducts...
generated by inflammation. In line with previous studies (33) we found no relationship between lung function and inflammation.

In summary, our study shows ozone effects on two independent markers of airway health at a level as low as 0.06 ppm in healthy young adults. We did not find a significant role of GSTM1 genotype alone on the ozone-induced airway effects, but there may be individuals or subpopulations with enhanced sensitivity (such as in asthma) at these levels. We therefore conclude that exposure to ozone levels below the current standard can cause changes in lung function and initiate an airway inflammatory response in young adult population and pose a health risk particularly to susceptible populations.

Acknowledgement

The authors thank the nurses and the technical staff of EPA, UNC and TRC for their invaluable assistance.

Disclaimer: Although the research described in this article has been supported by the United States Environmental Protection Agency, it has not been subjected to Agency review and therefore does not necessarily reflect the views of the Agency and no official endorsement should be inferred. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.
References


6. Adams WC. Comparison of chamber and face mask 6.6-hour exposure to 0.08 ppm ozone via square-wave and triangular profiles on pulmonary responses. Inhal Tox 2003; 15:265-81.

7. Adams WC. Comparison of chamber 6.6-h exposure to 0.04-0.08 ppm ozone via square-wave and triangular profiles on pulmonary responses. Inhal Tox 2006; 18: 127-36.


9. Devlin RB, McDonnell WF, Mann R, Becker S, House DE, Koren HS. Exposure of humans to ambient levels of ozone for 6.6 hours causes cellular and biochemical changes in the lung.


   Pulmonary response in healthy young adultys exposed to low concentration of ozone for 6.6 hours with mild exercise. Am J Respir Crit Care Med 2010; 181: A1728


Figure Captions

Figure 1 Percent changes in FEV$_1$ and FVC after 6.6 hour exposure to clean air and 0.06 ppm ozone. (A) and (B) show the group means (±SEM) and individual changes, respectively for FEV$_1$. (C) and (D) show the group means (±SEM) and individual changes, respectively for FVC.

Figure 2 Clean air adjusted % changes (mean and 95% confidence interval) in FEV$_1$ (A) and FVC (B) after ozone exposure for all subjects, and by gender and GSTM1 genotype. M and F represent males and females, respectively. * represents p<0.05 and † represents 0.05<p<0.1

Figure 3 %PMN changes in sputum samples after 6.6 hour exposure to clean air and 0.06 ppm ozone for the group mean (A) and each individual (B). Error bars represent standard error. % PMN is defined by neutrophil number as % of total cell counts in the sample.

Figure 4 Clean air adjusted % changes in PMN (mean and 95% confidence interval) after ozone exposure for all subjects, and by gender and GSTM1 genotype. M and F represent males and females, respectively. * represents p<0.05.
Figure 1

(A) * p=0.008

(B)

(C) * p=0.02

(D)
Figure 2

CA-adjusted FEV\(_1\) % Change

- All
- M
- F
- GSTM1-p
- GSTM1-n

CA-adjusted FVC % Change

- All
- M
- F
- GSTM1-p
- GSTM1-n

\(p=NS\)

\(*\)

\(\dagger\)
Figure 3

Figure 4
Table 1. Subject characteristics and baseline lung function measures

<table>
<thead>
<tr>
<th></th>
<th>All subjects</th>
<th>Males</th>
<th>Females</th>
<th>GSTM1-p</th>
<th>GSTM1-n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>59</td>
<td>27</td>
<td>32</td>
<td>30</td>
<td>29</td>
</tr>
<tr>
<td>Age, year (years)</td>
<td>25.0 (0.5)</td>
<td>26.1 (0.9)</td>
<td>24.0 (0.5)</td>
<td>24.9 (0.8)</td>
<td>25.1 (0.7)</td>
</tr>
<tr>
<td>Height, cm</td>
<td>171.2 (1.2)</td>
<td>178.9 (1.2)</td>
<td>164.7 (1.0)</td>
<td>172.2 (1.5)</td>
<td>170.2 (1.9)</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>70.5 (1.8)</td>
<td>78.8 (2.3)</td>
<td>63.4 (2.1)</td>
<td>71.5 (2.5)</td>
<td>69.4 (2.6)</td>
</tr>
<tr>
<td>BSA, m²</td>
<td>1.8 (0.03)</td>
<td>2.0 (0.03)</td>
<td>1.7 (0.03)</td>
<td>1.8 (0.04)</td>
<td>1.8 (0.04)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>23.8 (0.48)</td>
<td>24.5 (0.72)</td>
<td>23.3 (0.64)</td>
<td>23.9 (0.68)</td>
<td>23.8 (0.69)</td>
</tr>
<tr>
<td>FEV₁, L</td>
<td>4.02 (0.10)</td>
<td>4.64 (0.12)</td>
<td>3.49 (0.07)</td>
<td>4.14 (0.12)</td>
<td>3.89 (0.16)</td>
</tr>
<tr>
<td>FVC, L</td>
<td>4.83 (0.13)</td>
<td>5.69 (0.14)</td>
<td>4.10 (0.11)</td>
<td>4.94 (0.17)</td>
<td>4.72 (0.21)</td>
</tr>
<tr>
<td>FEV₁/FVC, %</td>
<td>84.1 (0.8)</td>
<td>82.0 (1.1)</td>
<td>85.8 (1.2)</td>
<td>84.6 (1.2)</td>
<td>83.5 (1.2)</td>
</tr>
<tr>
<td>FEF₂₅-₇₅%, L/s</td>
<td>4.22 (0.14)</td>
<td>4.64 (0.23)</td>
<td>3.87 (0.14)</td>
<td>4.39 (0.21)</td>
<td>4.05 (0.18)</td>
</tr>
<tr>
<td>FEF₉₀, L/s</td>
<td>9.03 (0.25)</td>
<td>10.61 (0.28)</td>
<td>7.69 (0.17)</td>
<td>9.49 (0.35)</td>
<td>8.54 (0.34)</td>
</tr>
</tbody>
</table>

Values are mean (±SEM); BSA, body surface area; BMI, body mass index;
FEV₁, forced exhaled volume in first 1 sec; FVC, forced vital capacity;
FEF₂₅-₇₅%, forced expiratory flow between 25% and 75% of FVC;
FEF₉₀, maximum forced expiratory flow
GSTM1, glutathione S-transferase Mu 1; the qualifier p and n represent positive and null, respectively.
Table 2. Breathing parameters and heart rate of subjects during 6.6 hour exposure

<table>
<thead>
<tr>
<th></th>
<th>$V_E$ (L/min)</th>
<th>$V_t$ (L)</th>
<th>$f$ (min$^{-1}$)</th>
<th>Heart rate (min$^{-1}$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clean air</td>
<td>37.1 (0.2)</td>
<td>1.38 (0.05)</td>
<td>29.1 (0.9)</td>
<td>128.4 (1.1)</td>
</tr>
<tr>
<td>Ozone</td>
<td>36.5 (0.2)</td>
<td>1.37 (0.05)</td>
<td>29.0 (0.9)</td>
<td>127.0 (1.1)</td>
</tr>
</tbody>
</table>

Values are mean (±SEM); $V_E$, minute ventilation; $V_t$, tidal volume; $f$, breathing frequency.

Note that the target value of $V_E = 20$ L/min/m$^2$ BSA corresponds to unadjusted mean value of 36.5 L/min.
Table 3. Lung function responses to 6.6 hour exposure to clean air (CA) and 0.06 ppm ozone in healthy young adults.

<table>
<thead>
<tr>
<th></th>
<th>All subjects (n=59)</th>
<th>Males (n=27)</th>
<th>Females (n=32)</th>
<th>GSTM1-p (n=30)</th>
<th>GSTM1-n (n=29)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%Δ</td>
<td>95% CI</td>
<td>%Δ</td>
<td>95% CI</td>
<td>%Δ</td>
</tr>
<tr>
<td><strong>FEV&lt;sub&gt;1&lt;/sub&gt;</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clean air</td>
<td>-0.002(0.46)</td>
<td>-0.9, 0.9</td>
<td>0.59(0.53)</td>
<td>-0.5, 1.6</td>
<td>-0.51(0.72)</td>
</tr>
<tr>
<td>Ozone</td>
<td>-1.76(0.50)</td>
<td>-2.7, -0.8</td>
<td>-0.85(0.62)</td>
<td>-2.1, 0.4</td>
<td>-2.52(0.74)</td>
</tr>
<tr>
<td>Ozone-CA</td>
<td>-1.75(0.64)*</td>
<td>-3.0, -0.5</td>
<td>-1.44(0.95)</td>
<td>-3.4, 0.5</td>
<td>-2.02(0.88)*</td>
</tr>
<tr>
<td><strong>FVC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clean air</td>
<td>-1.13(0.34)</td>
<td>-1.8, -0.5</td>
<td>-0.77(0.33)</td>
<td>-1.4, -0.1</td>
<td>-1.44(0.56)</td>
</tr>
<tr>
<td>Ozone</td>
<td>-2.32(0.41)</td>
<td>-3.1, -1.5</td>
<td>-1.26(0.52)</td>
<td>-2.3, -0.2</td>
<td>-3.22(0.57)</td>
</tr>
<tr>
<td>Ozone-CA</td>
<td>-1.19(0.51)*</td>
<td>-2.2, -0.2</td>
<td>-0.49(0.74)</td>
<td>-2.0, 1.0</td>
<td>-1.78(0.68)*</td>
</tr>
</tbody>
</table>

n, number of subjects; <sup>a</sup>, % change relative to preexposure, mean(±SEM); <sup>b</sup>, 95% confidence interval; *, p<0.05

FEV<sub>1</sub>, forced expired volume at 1 s; FVC, forced vital capacity;

GSTM1, glutathione S-transferase Mu 1; the qualifier p and n represent positive and null, respectively.
Table 4. PMN responses to 6.6 hour exposure to clean air (CA) and 0.06 ppm ozone in healthy young adults.

<table>
<thead>
<tr>
<th></th>
<th>All subjects</th>
<th>Males (n=11)</th>
<th>Females (n=13)</th>
<th>GSTM1-p (n=12)</th>
<th>GSTM1-n (n=12)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (95% CI)</td>
<td>Mean (95% CI)</td>
<td>Mean (95% CI)</td>
<td>Mean (95% CI)</td>
<td>Mean (95% CI)</td>
</tr>
<tr>
<td>%PMN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clean air</td>
<td>38.3(3.7)</td>
<td>33.4(5.3)</td>
<td>42.4(5.1)</td>
<td>34.7(5.6)</td>
<td>41.9(4.8)</td>
</tr>
<tr>
<td>Ozone</td>
<td>54.0(4.6)</td>
<td>57.6(6.4)</td>
<td>50.9(6.6)</td>
<td>46.1(6.7)</td>
<td>61.9(5.5)</td>
</tr>
<tr>
<td>Ozone-CA</td>
<td>15.7(3.1)*</td>
<td>24.2(4.3)*</td>
<td>8.5(3.7)*</td>
<td>11.3(4.5)*</td>
<td>20.0(4.6)*</td>
</tr>
<tr>
<td>Total cell count</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clean air</td>
<td>5.05x10^6 (0.82)</td>
<td>4.08x10^6 (0.98)</td>
<td>5.86x10^6 (1.26)</td>
<td>3.97x10^6 (0.90)</td>
<td>6.13x10^6 (1.34)</td>
</tr>
<tr>
<td>Ozone</td>
<td>6.93x10^6 (1.52)</td>
<td>9.42x10^6 (3.03)</td>
<td>4.83x10^6 (0.96)</td>
<td>5.58x10^6 (2.23)</td>
<td>8.28x10^6 (2.10)</td>
</tr>
</tbody>
</table>

n, number of subjects; %PMN, polymorphonuclear neutrophils as % of total cell counts, mean(±SEM); SEM (standard error) of total cell count is for the base number of 10^6; CI, confidence interval; *, p<0.05; GSTM1, glutathione S-transferase Mu 1; the qualifier p and n represent positive and null, respectively.
Online Data Supplement

Lung Function and Inflammatory Responses in Healthy Young Adults Exposed to 0.06 ppm Ozone for 6.6 Hours

Chong S Kim¹, Neil E Alexis², Ana G Rappold¹, Howard Kehrl¹, Milan J Hazucha², John C Lay², Mike T Schmitt¹, Martin Case¹, Robert B Devlin¹, David B Peden², and David Diaz-Sanchez¹

Ambient ozone monitoring

During the four months study period (November to March), hourly maximum concentration stayed mostly below 0.04 ppm during the month from November to February. Ozone concentration started going up during the month of March, occasionally overshooting into the range of 0.05 ppm but rarely exceeding 0.06 ppm. A figure of hourly maximum ozone concentration from November to March monitored in the Millbrook Monitoring Station (approximately 30 miles East from Chapel Hill) is shown in Figure E1. Millbrook Station is located near the urban center of the city of Raleigh (Chapel Hill does not have a State Monitoring Station) where ambient ozone concentration is expected to be greater, if there are any differences, than Chapel Hill.

![Hourly Maximum Ozone Concentration](image)

Figure E1. Hourly maximum ozone concentration monitored in Millbrook Monitoring Station in Raleigh, North Carolina during the month of winter season.